Publications by authors named "Laura S Angelo"

23Publications

CXCR6 NK Cells in Human Fetal Liver and Spleen Possess Unique Phenotypic and Functional Capabilities.

Front Immunol 2019 19;10:469. Epub 2019 Mar 19.

Department of Pediatrics, Center for Human Immunobiology, Texas Children's Hospital, Houston, TX, United States.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.00469
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.00469DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433986PMC
September 2020

Genome-wide analyses and functional profiling of human NK cell lines.

Mol Immunol 2019 11 24;115:64-75. Epub 2018 Jul 24.

Department of Pediatrics, Columbia University Irving Medical Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2018.07.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345623PMC
November 2019

Mutations in PI3K110δ cause impaired natural killer cell function partially rescued by rapamycin treatment.

J Allergy Clin Immunol 2018 08 10;142(2):605-617.e7. Epub 2018 Jan 10.

Center for Human Immunobiology, Texas Children's Hospital, Houston, Tex; Department of Pediatrics, Baylor College of Medicine, Houston, Tex. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2017.11.042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109967PMC
August 2018

Practical NK cell phenotyping and variability in healthy adults.

Immunol Res 2015 Jul;62(3):341-56

Center for Human Immunobiology, Department of Allergy, Immunology and Rheumatology, The Feigin Center, Texas Children's Hospital, 1102 Bates Street, Suite 330, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12026-015-8664-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470870PMC
July 2015

NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations.

Oncotarget 2014 Jan;5(1):67-77

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960189PMC
http://dx.doi.org/10.18632/oncotarget.1557DOI Listing
January 2014

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.

Oncotarget 2013 Jun;4(6):884-9

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757245PMC
http://dx.doi.org/10.18632/oncotarget.1021DOI Listing
June 2013

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.

Oncotarget 2013 Mar;4(3):463-73

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/886
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717308PMC
http://dx.doi.org/10.18632/oncotarget.886DOI Listing
March 2013

Binding partners for curcumin in human schwannoma cells: biologic implications.

Bioorg Med Chem 2013 Feb 13;21(4):932-9. Epub 2012 Dec 13.

Department of Investigational Cancer Therapeutics, (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2012.12.008DOI Listing
February 2013

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.

PLoS One 2011 11;6(10):e26060. Epub 2011 Oct 11.

Phase I Program, Department of Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026060PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191161PMC
February 2012

Combining curcumin (diferuloylmethane) and heat shock protein inhibition for neurofibromatosis 2 treatment: analysis of response and resistance pathways.

Mol Cancer Ther 2011 Nov 8;10(11):2094-103. Epub 2011 Sep 8.

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0243DOI Listing
November 2011

Target validation using Phase 0 clinical trials: Promises and pitfalls.

Cancer Biol Ther 2009 Nov;8(21):2010-2

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.8.21.10154DOI Listing
November 2009

Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.

Cancer Biol Ther 2009 Dec 2;8(23):2239-47. Epub 2009 Dec 2.

Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.8.23.9986DOI Listing
December 2009

Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.

Mol Cancer Ther 2009 Mar 3;8(3):703-10. Epub 2009 Mar 3.

Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Unit 455, P.O. Box 301402, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0656DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679515PMC
March 2009

Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia.

Clin Cancer Res 2009 Feb;15(4):1123-5

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2791DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646173PMC
February 2009

Interleukin-6 and its receptor in cancer: implications for translational therapeutics.

Cancer 2007 Nov;110(9):1911-28

Phase I Program, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22999DOI Listing
November 2007

Vascular endothelial growth factor and its relationship to inflammatory mediators.

Clin Cancer Res 2007 May;13(10):2825-30

Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-2416DOI Listing
May 2007

Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53.

Cancer Res 2002 Feb;62(3):932-40

Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
February 2002